ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: Paul Van Nevel, Director Of NCI Communications, To Retire At Year’s End

November 26, 1999

Pesticides Increase Leukemia Risk, USA Investigations Report

July 17, 1987

NCCN Launches Outcomes Improvement Program

August 12, 2011

DCT Board Approves New Imaging Study In Split Vote, Small Grant Program

October 27, 1989

NCI Begins Phase III Trial Of Shark Cartilage In NSCLC.

May 25, 2001

In Brief: Carcinogenesis Task Force to Wrap Up Review In Four-Six Weeks; UCLA Groundbreaking Set

October 28, 1977